Synaptogenix (TAOX) Stock Price, News & Analysis

Company Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Key Stats

• Today's Range: $5.74 to $6.40
• 50-Day Range: N/A
• 52-Week Range: $1.84 to $11.98
• Volume: 231,593 shs
• Average Volume: 209,137 shs
• Market Capitalization: $21.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Synaptogenix Stock Analysis - MarketRank™

Synaptogenix scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Synaptogenix.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Synaptogenix is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Synaptogenix is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Synaptogenix has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.43% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Synaptogenix does not currently pay a dividend.

Dividend Growth

Synaptogenix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.43% of the float of Synaptogenix has been sold short.

Short Interest Ratio / Days to Cover

Synaptogenix has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.95

News Sentiment

Synaptogenix has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.21 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Synaptogenix this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Synaptogenix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.73% of the stock of Synaptogenix is held by insiders.

Percentage Held by Institutions

Only 10.34% of the stock of Synaptogenix is held by institutions.

TAOX Stock Analysis - Frequently Asked Questions

How have TAOX shares performed this year?

Synaptogenix's stock was trading at $8.41 at the start of the year. Since then, TAOX shares have decreased by 26.2% and is now trading at $6.21.

How were Synaptogenix's earnings last quarter?

Synaptogenix, Inc. (NASDAQ:TAOX) announced its quarterly earnings data on Friday, August, 15th. The company reported ($11.26) earnings per share for the quarter.

How do I buy shares of Synaptogenix?

Shares of TAOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/15/2025
• Today: 9/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TAOX
• CIK: 1571934
• Web: N/A
• Phone: (973) 242-0005
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($20.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.77 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -277.76%
• Return on Assets: -150.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.52
• Quick Ratio: 20.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.33 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 3,490,000
• Free Float: 3,392,000
• Market Cap: $21.67 million
• Optionable: N/A
• Beta: 1.87